News Focus
News Focus
Followers 25
Posts 2991
Boards Moderated 2
Alias Born 10/18/2003

Re: DewDiligence post# 862

Sunday, 04/15/2007 4:46:47 PM

Sunday, April 15, 2007 4:46:47 PM

Post# of 3757
Anyone have any comments on McHutchison's comments referencing VRTX's compound. Shortening length of treatment is HUGE, quite an endorsement from McHutchison.

"The high rates of RVR observed in the telaprevir groups in PROVE 1, and the fact that some patients have remained persistently viral negative 20 weeks after stopping the 12 weeks of telaprevir-based therapy, suggest that we may be able to shorten the treatment duration in genotype 1 HCV patients," said John McHutchison, M.D., Principal Investigator for the PROVE 1 study and Director of Gastroenterology and Hepatology Research at Duke Clinical Research Institute. "These interim results are encouraging and suggest that high sustained viral response (SVR) rates may be achieved with regimens that are 24 weeks in total duration. We look forward to 24 week follow-up data from the initial group of patients who stopped treatment at 12 weeks, and follow-up data from patients in the study who received 24 weeks of treatment."



katie...
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y